For laboratory research use only - not for human consumption

Hub · Peptide Quality & Verification

TB-500 vs thymosin beta-4: is TB-500 the same molecule?

TB-500 is not the same molecule as thymosin beta-4. Thymosin beta-4 is a natural protein 43 amino acids long (Low et al., 1981). Amino acids are the small units that proteins are built from. In the papers that define it, TB-500 is a synthetic fragment. A fragment is a short piece of that chain. Here it is made in a laboratory. It has seven amino acids, LKKTETQ. It has an acetyl group on the first one. An acetyl group is a small chemical tag (Ho et al., 2012).

Published 2026-10-04Updated 2026-10-04Written by Form Laboratories research team5 min read

Your cells keep their shape with an inner scaffold of thread-like protein. The threads are built from a protein called actin. UniProt is a public protein database. It records thymosin beta-4 as a binder of single actin units (UniProt P62328). A 2010 review calls it the major actin-sequestering molecule in cells with a nucleus. That means it holds actin units in reserve (Sosne et al., 2010).

This page is part of the peptide quality & verification hub. There, a peptide means a short chain of amino acids. The page asks one naming question. When someone writes TB-500, which molecule is meant? Research papers that give an exact amino-acid sequence answer it. A sequence is the order of units along a chain.

  • Guidepeptide quality & verification hubHow research peptides are tested and verified: purity methods, certificates of analysis, batch traceability, and what each document can and cannot tell you.

Key facts

Key facts for TB-500 vs thymosin beta-4: is TB-500 the same molecule?
Parent proteinThymosin beta-4, 43 amino acids long (Low et al., 1981)
TB-500 as defined in two papersAc-LKKTETQ, where Ac- is the acetyl tag; 7 amino acids (Ho et al., 2012; Esposito et al., 2012)
Fragment positionPositions 17 to 23 of the 43 (Sosne et al., 2010)
Protein recordUniProt P62328, an entry in a public protein database
Evidence used hereIdentity and sequence findings only; no effect findings used
PNAS 1981Journal of Chromatography A 2012Drug Testing and Analysis 2012

Is TB-500 the same as thymosin beta-4?

TB-500 is not the same as thymosin beta-4 in the papers that define the two. Thymosin beta-4 is a protein of 43 amino acids (Low et al., 1981). Each letter in its sequence stands for one unit of the chain. Two laboratory-testing papers define TB-500 as the seven-unit peptide Ac-LKKTETQ. It sits at positions 17 to 23 of that protein. It has an acetyl group added to its first unit (Esposito et al., 2012; Ho et al., 2012). A fragment is a short piece of a longer molecule. So TB-500 is a piece of thymosin beta-4, not the whole protein.

PNAS 1981UniProt P62328FASEB Journal 2010

What is full-length thymosin beta-4?

Thymosin beta-4 is a natural protein of 43 amino acids. It was sequenced from calf thymus in 1981 (Low et al., 1981). The thymus is a small gland in the chest. UniProt lists the human sequence in groups of ten letters: SDKPDMAEIE KFDKSKLKKT ETQEKNPLPS KETIEQEKQA GES. It leaves out the starting amino acid, methionine, which the cell removes. It records an acetylated serine at the first position (UniProt P62328). Serine is an amino acid. The same entry says the protein binds and sequesters actin monomers. That means it holds single actin units and stops them joining into threads. A 2010 review names the stretch LKKTETQ, at positions 17 to 23, as the central actin-binding part of the protein (Sosne et al., 2010).

The sequence is a string of letters, so it reads like a sentence. The first four letters, SDKP, form a different named part, Ac-SDKP. TB-500 does not include it (Sosne et al., 2010).

Journal of Chromatography A 2012Drug Testing and Analysis 2012

What is the TB-500 fragment, and how do papers identify it?

A 2012 paper on testing horse samples describes TB-500 as a veterinary preparation. That is a product made for animal use. Its key ingredient is LKKTETQ with an artificial acetyl group on its first end (Ho et al., 2012). A second 2012 paper detected Ac-LKKTETQ inside TB-500. It used high-performance liquid chromatography with high-resolution mass spectrometry. That method separates a mixture and weighs each molecule. The paper also made the fragment by chemical synthesis (Esposito et al., 2012). In both papers the name TB-500 is tied to a stated sequence and a stated acetyl tag. That is what makes the identity checkable.

The name alone does not settle identity. The letters and the tag are what a laboratory can test. The TB-500 research guide collects the published studies in one place.

  • GuideTB-500 research guideA plain-English guide to TB-500: the actin-binding fragment of thymosin beta-4, what's been studied, and why it isn't the same as the full protein.
Wound Repair and Regeneration 2003

Evidence limits

Does the name TB-500 always mean this exact fragment?

No source on this page shows that every product or study called TB-500 contains Ac-LKKTETQ. Ho et al. (2012) and Esposito et al. (2012) each name the sequence and the acetyl tag for the material they examined. That is evidence about those preparations only. A 2003 animal study abstract names the seven-unit peptide LKKTETQ. It does not say whether the peptide carried an acetyl tag (Philp et al., 2003). So that abstract alone cannot be matched to Ac-LKKTETQ. A label, a catalogue name or a paper that says TB-500 without the sequence and the tag leaves the identity open.

A researcher holding paperwork can ask whether a batch record names the sequence and the tag. How to read a certificate of analysis covers the fields. What a batch or lot number lets a researcher verify covers the code that ties a vial to its record. The catalogue entry is TB-500 reference material.

Comparison

Each row compares one checkable property. Every cell names its source. No row describes effects.

Comparison: TB-500 vs thymosin beta-4: is TB-500 the same molecule?
PropertyThymosin beta-4 (full length)TB-500 (as defined in the papers)
Length43 amino acids (Low et al., 1981)7 amino acids (Ho et al., 2012)
PositionPositions 1 to 43 (Sosne et al., 2010)Positions 17 to 23 of the 43 (Ho et al., 2012)
Sequence in one-letter codes (one letter per amino acid)SDKPDMAEIE KFDKSKLKKT ETQEKNPLPS KETIEQEKQA GES (UniProt P62328)LKKTETQ (Ho et al., 2012)
Acetyl tagOn the first unit, serine (Low et al., 1981; UniProt P62328)On the first unit, the amino acid leucine, added artificially (Ho et al., 2012)
OriginNatural protein, sequenced from calf thymus (Low et al., 1981)Synthetic version of the fragment (Ho et al., 2012)
First four positionsHold the named part Ac-SDKP (Sosne et al., 2010)Lie outside the fragment, which spans positions 17 to 23 (Ho et al., 2012)

FAQ

Is TB-500 a fragment of thymosin beta-4?

TB-500 is described as a fragment of thymosin beta-4. It is the seven-amino-acid stretch at positions 17 to 23, with an added acetyl tag (Ho et al., 2012; Sosne et al., 2010).

Is thymosin beta-4 the same as Ac-SDKP?

Thymosin beta-4 is not the same as Ac-SDKP. Ac-SDKP is a four-amino-acid part at positions 1 to 4 of the protein. UniProt lists it as a peptide contained in thymosin beta-4 (Sosne et al., 2010; UniProt P62328). TB-500 covers positions 17 to 23 and does not include it (Ho et al., 2012).

Does Australian law list TB-500 and thymosin beta-4 as the same thing?

Australian law lists them separately. The Poisons Standard is the national list of controlled medicines and poisons. It names TB-500 and thymosin beta 4 (thymosin β4) as two entries. Each is in Schedule 4 (prescription-only medicines) and Appendix D, clause 5 (poisons that must not be possessed without authority). The source is the Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026, F2026L01327, checked 1 October 2026 UTC (universal time). Each entry is a name without a description.

Citations

5 sources
  1. Low TL, Hu SK, Goldstein AL. Proceedings of the National Academy of Sciences. 1981;78(2):1162-1166.
    doi:10.1073/pnas.78.2.1162

  2. Sosne G, Qiu P, Goldstein AL, Wheater M. FASEB Journal. 2010;24(7):2144-2151.
    doi:10.1096/fj.09-142307

  3. Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Journal of Chromatography A. 2012;1265:57-69.
    doi:10.1016/j.chroma.2012.09.043

  4. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Drug Testing and Analysis. 2012;4(9):733-738.
    doi:10.1002/dta.1402

  5. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Wound Repair and Regeneration. 2003;11(1):19-24.
    doi:10.1046/j.1524-475x.2003.11105.x

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease